Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4266591 | 1.00 | METAP2 (0.41) | METAP2METAP1SSTR4PDE2AMCHR1 | |
| SCHEMBL6462062 | 0.84 | MCHR1 (0.42) | METAP2METAP1SSTR4MCHR1EPHX2 | |
| SCHEMBL6457316 | 0.84 | MCHR1 (0.42) | METAP2METAP1SSTR4MCHR1EPHX2 | |
| SCHEMBL6464298 | 0.81 | METAP2 (0.42) | METAP2METAP1SSTR4MCHR1OPRM1 | |
| SCHEMBL6464312 | 0.81 | METAP2 (0.42) | METAP2METAP1SSTR4MCHR1OPRM1 | |
| SCHEMBL4036490 | 0.77 | MCHR1 (0.61) | METAP2METAP1MCHR1EPHX2 | |
| SCHEMBL4359947 | 0.77 | MCHR1 (0.61) | METAP2METAP1MCHR1EPHX2 | |
| SCHEMBL4258666 | 0.75 | MCHR1 (0.46) | MCHR1 | |
| SCHEMBL4258661 | 0.75 | MCHR1 (0.46) | MCHR1 | |
| SCHEMBL6460996 | 0.74 | MCHR1 (0.45) | METAP2METAP1MCHR1OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036448-A1 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMECUTICAL CO., LTD. (JP) | 2009-02-05 | — | — | US | claimed |
| US-20090036448-A1 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMECUTICAL CO., LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036448-A1 | PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | GPR119, HCRTR2, MCHR1 | METAP2 1852/4885METAP1 1804/4885SSTR4 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.